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Abstract
Introduction Infantile hypertrophic pyloric stenosis (IHPS) is caused by hypertrophy of the pyloric sphincter muscle.
Objectives Since previous reports have implicated lipid metabolism, we aimed to (1) investigate associations between IHPS 
and a wide array of lipid-related metabolites in newborns, and (2) address whether detected differences in metabolite levels 
were likely to be driven by genetic differences between IHPS cases and controls or by differences in early life feeding patterns.
Methods We used population-based random selection of IHPS cases and controls born in Denmark between 1997 and 
2014. We randomly took dried blood spots of newborns from 267 pairs of IHPS cases and controls matched by sex and day 
of birth. We used a mixed-effects linear regression model to evaluate associations between 148 metabolites and IHPS in a 
matched case–control design.
Results The phosphatidylcholine PC(38:4) showed significantly lower levels in IHPS cases (P = 4.68 × 10−8) as did six other 
correlated metabolites (four phosphatidylcholines, acylcarnitine AC(2:0), and histidine). Associations were driven by 98 
case–control pairs born before 2009, when median age at sampling was 6 days. No association was seen in 169 pairs born 
in 2009 or later, when median age at sampling was 2 days. More IHPS cases than controls had a diagnosis for neonatal dif-
ficulty in feeding at breast (P = 6.15 × 10−3). Genetic variants known to be associated with PC(38:4) levels did not associate 
with IHPS.
Conclusions We detected lower levels of certain metabolites in IHPS, possibly reflecting different feeding patterns in the 
first days of life.
1 Introduction
Infantile hypertrophic pyloric stenosis (IHPS), a disease 
typically appearing between two and eight weeks after 
birth, is characterized by hypertrophy of the pyloric sphinc-
ter smooth muscle, which leads to obstruction of the gastric 
outlet (MacMahon 2008). IHPS has a population incidence 
between 1 and 4 per 1000 live births (Pedersen et al. 2008; 
Kapoor et al. 2019), a 4- to 5-fold higher risk in boys than 
girls (MacMahon 2006), and is the most common disease 
requiring surgery in the first months of life (Chung 2008). 
Despite its well-established clinical presentation, diagnosis 
and treatment, IHPS etiology remains incompletely under-
stood, with both genetic and environmental factors contrib-
uting to disease pathogenesis. IHPS familial aggregation of 
20-fold increased risk among siblings (Krogh et al. 2010), 
twin heritability estimates of 87% (Krogh et al. 2010) and 
genome wide SNP heritability of 30% (Fadista et al. 2019) 
suggest a strong genetic component for IHPS. Furthermore, 
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perinatal risk factors such as exposure to macrolide antibiot-
ics (Lund et al. 2014), being first-born, preterm, delivery by 
cesarean section (Krogh et al. 2012a.1), and bottle-feeding 
(McAteer et al. 2013; Krogh et al. 2012b.2) highlight the 
importance of modifiable early environmental exposures on 
the risk of IHPS (Zhu et al. 2017).
Previous findings from our group and others showed an 
association between IHPS and lipid metabolism. Briefly, 
we detected genetic variants at the APOA1 locus in which 
known cholesterol-lowering alleles were associated with 
increased risk of IHPS (Feenstra et al. 2013). Moreover, in 
the same study we found lower levels of total cholesterol in 
umbilical cord blood in cases vs. controls (Feenstra et al. 
2013). In our most recent genome-wide association study 
(GWAS) meta-analysis of IHPS, we also detected a genome-
wide positive genetic correlation with high-density lipopro-
tein (HDL) cholesterol and a negative correlation with very 
low-density lipoprotein cholesterol (VLDL) (Fadista et al. 
2019). Moreover, 14% of children with Smith–Lemli–Opitz 
syndrome (SLOS), a malformation syndrome caused by an 
inborn defect of cholesterol biosynthesis (Tint et al. 1994), 
are reported to have IHPS (Kelley and Hennekam 2000).
Following on these previous findings, this study had two 
goals. The first goal was to investigate associations between 
IHPS and lipid-related metabolites in the blood of neonates 
from dried blood spot samples obtained through the routine 
Danish neonatal screening program (Nørgaard-Pedersen 
and Hougaard 2007). The second goal was to address the 
question of whether detected differences in metabolite levels 
were likely to be driven by genetic differences between IHPS 
cases and controls or by differences in early life feeding pat-
terns, i.e. breastfeeding vs. formula-feeding or feeding dif-
ficulties in the first days of life.
2  Methods
2.1  Study participants
Study participants were born between 1997 and 2014 and 
belong to a Danish ancestry cohort previously described 
in our genome-wide meta-analysis of IHPS (Fadista et al. 
2019). Briefly, whole blood from heel prick sampling of 
newborns was blotted on filter paper and stored as dried 
blood spot (DBS) samples as part of the routine Danish 
neonatal screening program. DBS samples from children 
born before 2009 had a median age of sampling of 6 days 
(5–8 days; 1st–3rd quartiles), while children born from 2009 
onwards had a median age at sampling of 2 days (2–3 days; 
1st–3rd quartiles) (Supplemental Fig. 1). IHPS cases were 
defined as having a pyloromyotomy (registered in the Danish 
National Patient Register (Lynge et al. 2011)) in their first 
year of life, were singletons born in Denmark with parents 
and grandparents born in Northwestern Europe, and were 
born with no severe pregnancy complications nor major con-
genital malformations (see Fadista et al. 2019). For controls 
we used the same selection criteria as for cases, but without 
any IHPS diagnosis or surgery code. The initial sample size 
comprised a total of 588 samples (3.2 mm punches) taken 
from DBS cards (294 pairs of cases and controls matched 
by sex and day of birth), of which we removed sequentially 
the following samples: (a) 2 pairs due to low sample quality 
in the cases; (b) 19 pairs due to at least one of the samples 
in each pair not passing standard GWAS QC (e.g. genetic 
variant missingness, ancestry outlier or genetic relatedness) 
(Fadista et al. 2019); (c) 5 pairs in which the controls had 
missing parity information; and (d) 1 pair in which the case 
had missing gestational age information. After this filtering, 
the discovery cohort comprised 267 pairs of IHPS cases and 
controls matched by sex and day of birth (range from 1997 to 
2014) (Table 1, Supplemental Fig. 2). The 267 IHPS cases 
represent a random 1/3 of all surgery confirmed cases in 
Denmark in the first year of life during the study period of 
1997 up to 2014 (http://bioba nks.dk/). All 534 samples were 
selected from DBS samples taken a few days after birth and 
stored in the Danish Neonatal Screening Biobank (Nørgaard-
Pedersen and Hougaard 2007). Sex, date of birth, gestational 
age, maternal age, Apgar scores (a standardized assessment 
score for infants after delivery) and parity information were 
extracted from the Danish Medical Birth Register (Blid-
dal et al. 2018), while diagnosis and surgery codes were 
extracted from the Danish National Patient Register (Lynge 
et al. 2011). Information on DBS sampling days after birth 
was available since 2006 in the Danish Neonatal Screening 
database. Sample summary characteristics are described in 
Table 1. This study was approved by the Danish Scientific 
Ethics Committee and the Danish Data Protection Agency. 
An exemption from obtaining informed consent from par-
ticipants was given as this research project was based on 
samples from biobank material (H-4-2013-055).
2.2  Metabolite profiling and nomenclature
The DBS samples consist of whole blood blotted onto fil-
ter paper, dried at room temperature for at least 3 h before 
being sent by mail for newborn screening at Statens Serum 
Institut. After newborn screening, the samples were then 
stored at − 20 °C in the Danish National Biobank (Nørgaard-
Pedersen and Hougaard 2007). On the day of the analysis, 
we collected a 3.2-mm punch using a Panthera-PuncherTM 
9 blood spot punching system (PerkinElmer, Waltham, MA, 
USA) directly into the 96-well kit plates.
Targeted metabolite quantification followed the manufac-
turer’s user manual for the AbsoluteIDQ® p400 Kit (Bio-
crates Life Sciences AG, Innsbruck, Austria), adapted for 
DBS analysis by the manufacturer (Biocrates 2018.1). The 
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kit has a high-performance liquid chromatography (LC) sep-
aration step and a flow injection analysis (FIA) step, both 
followed by mass spectrometry (MS) analyses. Mass detec-
tion and compound identification are performed by multiple 
reaction monitoring. The method of the AbsoluteIDQ® p400 
kit gives accurate results with good inter-laboratory preci-
sion for serum and plasma analysis (Thompson et al. 2019). 
Moreover, it has comparable results to the AbsoluteIDQ® 
p180 kit (Biocrates 2018.2), a kit with reported high inter-
laboratory reproducibility (Siskos et al. 2017), and validated 
for human blood plasma and DBS (Zukunft et al. 2013). The 
AbsoluteIDQ® p400 kit allows simultaneous quantification 
of 408 metabolites comprising 55 acylcarnitines, 21 amino 
acids, 21 biogenic amines, 196 glycerophospholipids (24 
lysophosphatidylcholines and 172 phosphatidylcholines), 
40 sphingolipids (31 sphingomyelins and 9 ceramides), 
hexoses (about 90–95% glucose), 14 cholesterol esters and 
60 glycerides (18 diglycerides and 42 triglycerides). Lipid 
metabolites are abbreviated as follows: acylcarnitines as 
AC(X:Y); hydroxylacylcarnitines as AC(X:Y-OH); dicar-
boxylacylcarnitines as AC(X:Y-DC); phosphatidylcholines 
as PC(X:Y); lysophosphatidylcholines as LPC(X:Y); sphin-
gomyelins as SM(X:Y); ceramides as Cer(X:Y); cholesterol 
esters as CE(X:Y); diglycerides as DG(X:Y) and triglyc-
erides as TG(X:Y). Each lipid metabolite is mentioned as 
X:Y, with X being the number of carbon atoms and Y the 
number of double bonds. Quality was controlled on each 
plate by the injection of three paper-based blanks and three 
quality control (QC) levels (QC1-3), of which the medium 
level (QC2) was injected in five replicates. We calculated 
absolute concentrations based on 7-point calibration curves 
for LC-MS metabolites and 1-point calibration for FIA-MS 
metabolites.
The equipment (Thermo Fisher Scientific, Waltham, MA, 
USA) consisted of a Combi PAL HTS TMO autosampler, 
a LX-2 LC system with two injectors, each connected to 
an Ultimate 3000 Dionex RS pump and to the MS through 
a Transcend II Valve Interface Module. MS data was 
acquired on a QExactive with a heated electrospray ioniza-
tion source. All solvents that were not provided with the kit 
were Optima™ LC/MS grade and purchased from Thermo 
Fisher Scientific. We controlled the instruments using Trace-
Finder 4.1 Clinical Research, Aria MX V2.2 and QExactive 
tune software V2.8 SP1.
We first injected extracts for LC-MS measurements on 
one dedicated injector (amino acids, biogenic amines). We 
conducted FIA the next day on the second dedicated injector 
(acylcarnitines, glycerophospholipids, sphingolipids, hex-
oses, cholesterol esters, glycerides). We ran eight 96-well 
plates, with wells measured in a fixed order (from #1 to 
#96). A matched case and control would always be on the 
same plate but not necessarily injected sequentially. We pre-
processed LC-MS data using Xcalibur 4.1, and integrated all 
data in Biocrates MetIDQ Carbon-2793 software for quality 
assessment, quantification of metabolite concentrations by 
reference to appropriate internal standards, and to do inter- 
and intra-plate normalization using the median value of the 
five QC2 replicated injections of each plate in comparison 
with their target values (see below).
2.3  Data cleaning and statistical analysis
After quantification, we performed data cleaning of the 408 
quantified metabolites, resulting in a reduced set of quality 
controlled metabolites for the association analyses. For each 
metabolite m and plate p, we defined the limit-of-detection 
 (LODm,p) as the median non-normalized values of metabo-
lite m for paper-based blanks (done in triplicate for each 
plate) on the relevant plate p. This means that LODs were 
calculated separately for each plate. We excluded a metabo-
lite m, if more than 20% of non-normalized concentrations in 
cases and controls were ≤ LOD. We implemented MetIDQs 
Table 1  Study sample 
characteristics
a The Apgar score is a standardized assessment for infants after delivery. It is based on a total score of 1 to 
10, with the higher the score, the better the newborn is doing after birth
Cases (N = 267) Controls (N = 267)
Boys, no. (%) 233 (87.3) 233 (87.3)
Year of birth (range) 1997–2014 1997–2014
Year of birth, mean (SD) 2008 (4.6) 2008 (4.6)
Maternal age, mean (SD), years 29.8 (5.3) 30.5 (4.8)
Gestational age, mean (SD), weeks 39.8 (1.7) 40.0 (1.4)
Parity, mean (SD) 1.7 (1.0) 1.8 (0.8)
Apgar  scoresa, mean (SD) 9.8 (0.7) 9.9 (0.4)
Age at DBS sampling, mean (SD), days 3.3 (2.2) 3.2 (1.8)
Age at diagnosis, mean (SD), days 36.8 (18.1)
Breastfeeding difficulty (P92.5), no. (%) 17 (6.4) 4 (1.5)
Cesarean section, no. 57 (21.3) 45 (16.9)
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data normalization procedure in R (R Core Team 2018), to 
scale out differences between plates. Briefly, we calculated 
the median value per metabolite per plate of the five rep-
licated injections of the QC2  (Am,p) (only for cells above 
LOD) and divided that by the metabolite target value  (TVm) 
of each metabolite, available in the MetIDQ database, lead-
ing to the correction factor by plate  (Am,p/TVm =  Cm,p). Then 
to normalize the data, we divided the raw concentration val-
ues of all samples by the plate-specific correction factor: 
 Normm,p =  Rawm,p/Cm,p. We also did metabolite filtering by 
coefficient of variation (CV) based on the normalized values 
of the QC2 replicates. For each metabolite m, we calculated 
its CV for all plates together, i.e. for 5 QC2 samples and 
8 plates, the CV was based on 40 observations. If  CVm > 
25% we excluded metabolite m. Thus, of the 408 metabolites 
measured with the kit, we therefore selected 148 metabolites 
that were above the limit of detection (LOD) in at least 80% 
of the samples (in cases or controls separately) and had a 
coefficient of variation of the QC2 replicates below 25%.
Due to the non-normal distribution of metabolite con-
centrations (reported in µM), we quantile transformed the 
normalized metabolite concentrations to a standard normal 
distribution prior to all statistical analyses. We performed 
estimation of association of metabolite levels with IHPS 
with a linear mixed-effects model, implemented in the 
lmer function from the lme4 R package (Bates et al. 2015), 
adjusted for sex (as factor), year of birth (as factor), parity, 
and gestational age (in weeks) as fixed effects, and IHPS 
case–control pair as a random effect. We defined a statisti-
cally significant association as P < 0.05/148, to adjust for 
the 148 metabolites tested (Bonferroni correction). We also 
performed a sensitivity analysis adding cesarean section (as 
factor) to the model.
Since the year 2009 marked a change of policy of the 
Danish neonatal screening program regarding age at sam-
pling of DBS samples, from a median of 6 days to 2 days 
after birth (Supplemental Fig. 1), we also performed strati-
fied association analyses for individuals born before 2009 
and for individuals born from 2009 onwards, respectively.
2.4  Diagnosis codes and co‐occurrence with IHPS
We extracted all International Classification of Diseases 
(ICD) diagnosis codes from the 267 pairs of IHPS cases 
and controls from the Danish National Patient Register 
(Lynge et al. 2011). We used Fisher’s exact test for count 
data implemented in R (R Core Team 2018) to calculate the 
odds-ratio of occurrence of the ICD-code P92.5 (“Neonatal 
difficulty in feeding at breast”) in IHPS cases vs. controls. 
We estimated the association of PC(38:4) levels with occur-
rence of ICD-code P92.5 at day of birth vs. after day of birth 
with a linear model, implemented in the lm function from 
R (R Core Team 2018), adjusted for sex (as factor), year of 
birth, parity, and gestational age (in weeks) and IHPS status.
2.5  Genetic variants associated with metabolite 
levels
Since FADS1 SNP rs174547 is known to explain an appreci-
able proportion of PC(38:4) variance (11%) in adults (Dra-
isma et al. 2015), we chose it as an instrumental variable to 
test for association between genetically determined levels 
of PC(38:4) and IHPS risk. We assessed the association 
of FADS1 genetic variant rs174547 (Gieger et al. 2008; 
Suhre et al. 2011; Draisma et al. 2015) with IHPS based 
on the latest genome-wide meta-analysis of IHPS (Fadista 
et al. 2019). Since we previously detected genetic variants 
at the APOA1 locus in which known cholesterol-lowering 
alleles were associated with increased risk of IHPS (Feen-
stra et al. 2013), we estimated the association of the sentinel 
SNP (rs12721025) for IHPS at the APOA1 locus (Feenstra 
et al. 2013; Fadista et al. 2019) against all 148 metabolites. 
We determined the association of rs174547 (FADS1) and 
rs12721025 (APOA1) with metabolite levels in a linear 
model adjusted for IHPS status, sex, year of birth (as factor), 
parity, and gestational age (in weeks). We also conducted 
stratified analysis separately for individuals born from 2009 
onwards (lower age at sampling) and for individuals born 
before 2009 (higher age at sampling).
3  Results
3.1  Description of the cohort
We sampled a cohort comprising 267 pairs of IHPS cases 
and controls matched by sex and day of birth from DBS sam-
ples taken a few days after birth (Sect. 2). Key characteristics 
of the cohort are described in Table 1 and Sect. 2.
3.2  Targeted metabolomics and IHPS association
We chose a lipid-centric targeted quantitative metabo-
lomics platform for metabolic profiling of IHPS cases and 
controls (Sect. 2). Of the 408 metabolites measured with 
the Biocrates p400 Kit, 148 metabolites passed data clean-
ing and quality control (Sect. 2). Using a mixed-effects 
linear regression model (Sect. 2), seven of the 148 metab-
olites showed significantly lower levels in IHPS cases 
(Table 2; Fig. 1, Supplemental Table 1). The seven metab-
olites included acylcarnitine AC(2:0), the amino acid his-
tidine and five phosphatidylcholines (PC(38:4), PC(36:4), 
PC-O(36:4), PC(44:1) and PC(38:3)) (Table 2; Fig. 1, Sup-
plemental Figs. 3–8). The top IHPS associated metabo-
lite was phosphatidylcholine PC(38:4) (P = 4.68 × 10−8) 
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(Fig. 2), while the concentrations of the remaining six 
metabolites showed significant positive correlation with 
PC(38:4) (all correlations with P < 2.30 × 10−12; test 
for correlation between paired samples using Pearson’s 
product moment correlation coefficient) (Fig. 3). After 
correction for multiple comparisons, we only detected 
significant association of metabolite levels with IHPS for 
individuals born before 2009 but not from 2009 onwards 
(Table 2; Fig. 2, Supplemental Tables 2 and 3). We did 
not find evidence of association between sex and levels 
of PC(38:4) (sex effect in full model described above: 
Fig. 1  IHPS association with 148 metabolites tested. Dashed verti-
cal lines separate different metabolite classes. The dashed horizontal 
line marks the Bonferroni-adjusted significance level of P = 0.05/148. 
Blue and red dots represent metabolites with lower and higher levels 
in IHPS cases vs. controls, respectively. Case/control normalized con-
centration fold-changes are between 0.67 and 1.26
Fig. 2  Density plot of the distribution of the quantile transformed normalized concentration of PC(38:4) in our cohort of 267 pairs of IHPS cases 
and controls
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P = 0.59) (Supplemental Fig. 9, Supplemental Table 4). 
Levels of the other six IHPS associated metabolites were 
also not associated with sex when correcting for multiple 
testing (Supplemental Table 4). Moreover, there was also 
no evidence of association between gestational age, parity 
or cesarean section and levels of PC(38:4) when correcting 
for multiple testing (Supplemental Table 4).
3.3  IHPS‑associated metabolites may tag different 
feeding patterns between cases and controls
In adults the genetic variant rs174547, which is intronic in 
the FADS1 gene, has been reported to explain 11% of the 
variance in PC(38:4) levels (Draisma et al. 2015). In the 
neonatal cohort analyzed here, rs174547 was associated with 
the ratio of PC(38:4)/PC(38:3) (P = 5.83 × 10− 10) and with 
Fig. 3  Pairwise complete 
Pearson correlation between the 
quantile transformed normal-
ized concentrations of the seven 
significantly IHPS associated 
metabolites
Table 2  Associations of 
metabolites with IHPS. Results 
are shown for all pairs and 
stratified into pairs with year of 
birth < 2009 or ≥ 2009
Metabolites are ordered by P value in the main analysis including all birth years.. The effect size Beta is 
with respect to the quantile transformed normalized concentration levels of each metabolite (Sect. 2). P val-
ues of the metabolite associations significant after Bonferroni correction are highlighted in bold. Metabo-
lite nomenclature is available in Sect. 2
YOB year of birth, SE standard error, P P value of the association, d days
Metabolites 267 IHPS case/control pairs
(All YOB)
98 IHPS case/control pairs
(YOB < 2009; median age = 6 
d)
169 IHPS case/control pairs
(YOB ≥ 2009; median 
age = 2 d)
Beta SE P Beta SE P Beta SE P
PC(38:4) − 0.42 0.07 4.68E−08 − 0.71 0.12 1.28E−08 − 0.25 0.09 9.35E−03
PC(36:4) − 0.36 0.07 2.51E−06 − 0.59 0.13 1.46E−05 − 0.23 0.09 1.51E−02
PC-O(36:4) − 0.33 0.07 3.29E−06 − 0.68 0.12 3.44E−07 − 0.13 0.08 1.10E−01
PC(44:1) − 0.33 0.08 1.94E−05 − 0.44 0.13 1.08E−03 − 0.28 0.10 3.95E−03
Histidine − 0.34 0.08 2.01E−05 − 0.57 0.14 9.25E−05 − 0.22 0.09 2.17E−02
PC(38:3) − 0.32 0.08 7.39E−05 − 0.59 0.12 5.31E−06 − 0.16 0.10 1.34E−01
AC(2:0) − 0.25 0.07 2.60E−04 − 0.39 0.10 1.49E−04 − 0.17 0.09 6.42E−02
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PC(38:3) (P = 1.05 × 10−5), but not with PC(38:4) (P = 0.30) 
(Supplemental Fig. 10). For individuals born from 2009 
onwards (lower age at sampling), rs174547 was also associ-
ated with the ratio of PC(38:4)/PC(38:3) (P = 1.27 × 10−11) 
and with PC(38:3) (P = 2.92 × 10−6), but also not with 
PC(38:4) (P = 0.30) (Supplemental Fig. 11). For individu-
als born before 2009 (higher age at sampling), rs174547 was 
not associated with the ratio of PC(38:4)/PC(38:3) (P = 0.17) 
or PC(38:3) (P = 0.46), nor with PC(38:4) (P = 0.61) (Sup-
plemental Fig.  12). To investigate whether genetically 
determined levels of PC(38:4) are associated with IHPS, we 
tested the association of rs174547 with IHPS risk based on 
the latest IHPS GWAS meta-analysis (Fadista et al. 2019), 
but no association was found (odds ratio [OR] per rs174547-
C allele, 1.04; 95% confidence interval [CI]: 0.95–1.13; 
P = 0.38) (Supplemental Fig. 13). This suggests that factors 
other than genetics that influence PC(38:4) levels underlie 
the association of this metabolite with IHPS risk. Feeding 
pattern could be one such factor. Although there was no 
general information on feeding patterns, a larger number 
of IHPS cases (n = 17) than controls (n = 4) had a diagnosis 
code for neonatal difficulty in feeding at breast (ICD-10 code 
P92.5) in the Danish National Patient Register (OR, 4.46; 
95% CI: 1.43–18.46; P = 6.15 × 10−3) (Table 1, Sect. 2). Fur-
thermore, among the individuals who had the P92.5 code, 
the ones who received the code already on their day of birth 
had significantly lower levels of PC(38:4) than individuals 
receiving the code on a later day (p = 0.036, Supplemental 
Fig. 14), even after correcting for sex, year of birth, gesta-
tional age, parity and IHPS status.
The variant rs12721025 at the APOA1 locus known to 
be associated with IHPS (Feenstra et al. 2013; Fadista et al. 
2019), was not associated with any of the 148 metabolites 
after correcting for multiple testing (P > 0.05/148). Further-
more, rs174547 at the FADS1 locus, was not nominally sig-
nificantly associated with the seven metabolites associated 
with IHPS (P > 0.05) (Supplemental Table 5).
4  Discussion
In this case–control metabolomics study of IHPS, we identi-
fied seven metabolites to have significantly lower levels in 
newborns who later developed the disease. The metabolites 
included five PCs, acylcarnitine AC(2:0), and the amino 
acid histidine, all with concentration levels correlated with 
each other. The associations were driven by 98 case–control 
pairs born before 2009, when median age at sampling was 
6 days. We did not detect significant associations in the 169 
case–control pairs born in 2009 or later, when median age 
at sampling was 2 days.
Different lines of evidence indicate that our findings may 
reflect different feeding patterns between the IHPS cases and 
controls in the first days of life. Serum levels of PC(38:4) 
and the other associated metabolites are influenced by 
food intake and genetics. In adults, 11% of the variance in 
PC(38:4) levels is explained by the genetic variant rs174547 
in the FADS1 gene (Draisma et al. 2015). The FADS1 gene 
codes for the fatty acid delta-5 desaturase, a key enzyme 
in the metabolism of long-chain polyunsaturated omega-3 
and omega-6 fatty acids, which catalyzes desaturation of 
PC(38:3) to PC(38:4) (Gieger et al. 2008; Suhre et al. 2011; 
Draisma et al. 2015). However, rs174547 was not associated 
with IHPS in our neonatal cohort, nor was it associated with 
IHPS in our previous GWAS meta-analysis (Fadista et al. 
2019). This suggests that genetically determined levels of 
the metabolite PC(38:4) are not associated with IHPS risk, 
requiring another explanation for the observed association 
between PC(38:4) levels and IHPS. Our data and previous 
studies point to the importance of feeding patterns. Notably, 
PC(38:4) is known to be at higher levels in plasma (Uhl et al. 
2016) and dried blood spot (Prentice et al. 2015) samples 
from breast-fed infants compared to bottle-fed infants, and 
bottle-feeding is a well-known risk factor for IHPS (McA-
teer et al. 2013; Krogh et al. 2012a, 2012b; Zhu et al. 2017). 
Although feeding data were not available in our cohort, 
many more children who developed IHPS than controls had 
a P92.5 diagnosis code for difficulty in feeding at breast, sup-
porting the hypothesis that a higher proportion of cases were 
primarily bottle-fed. In addition, newborns who received the 
P92.5 diagnosis on their day of birth had significantly lower 
levels of PC(38:4) than individuals with this diagnosis given 
on a later day further supporting that differences in levels of 
this metabolite in our data can be attributed to differences in 
feeding patterns. Finally, it should be noted that right after 
birth, newborns’ milk intake (whether formula or breast-
milk) is very low but increases rapidly within the first week 
of life (Casey et al. 1986; Dollberg et al. 2001). Thus, the 
relative importance of feeding pattern variation vs. genetic 
variation on phosphatidylcholine levels and ratios is likely 
to increase considerably too. The fact that our associations 
with IHPS were driven by the smaller subset of newborns 
(n = 98 pairs) sampled at around 6 days of age and not by 
the ones (n = 169 pairs) sampled around 2 days after birth is 
striking in this respect, further supporting that our findings 
are likely to be attributable to feeding differences between 
IHPS cases and controls rather than genetic regulation of 
phosphatidylcholine levels.
While previous work studied the role of bottle feeding 
as a risk factor for IHPS (McAteer et al. 2013; Krogh et al. 
2012b), these have been mainly observational in nature, 
compiled from health registry data in the first weeks and 
months after birth. To the best of our knowledge, no previ-
ous study has shown data specifically as early as 2 days after 
birth. It could be that in newborns with genetic susceptibil-
ity towards IHPS, the disease risk is slowly potentiated by 
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bottle feeding (or other altered feeding patterns) affecting 
lipid metabolism, leading to a lag of weeks between birth 
and the first IHPS symptoms.
Similar to phosphatidylcholines, we also detected his-
tidine and the short-chain acylcarnitine AC(2:0) to be at 
significantly lower concentrations in IHPS (Fig. 1; Table 2, 
Supplemental Figs. 6 and 7). Histidine is an essential amino 
acid (Kopple et al. 1975), i.e. it cannot be synthesized de 
novo in humans and therefore needs to be supplied in the 
diet. Moreover, histidine content is known to be higher 
in breast milk compared to standard liquid infant formu-
las (Agostoni et al. 2000) (preferred formulas in the first 
days of life). Similarly, it has been reported that infants 
who are breast-fed have higher concentrations of AC(2:0) 
in their plasma compared to bottle-fed infants (Kirchberg 
et al. 2015). These observations are also consistent with the 
hypothesis that controls were breast-fed to a higher extent 
than cases.
Further studies are needed to determine whether altered 
phosphatidylcholines, histidine and acylcarnitine AC(2:0) 
play a causative role in the pathogenesis of IHPS. It is also 
possible that these metabolites are just markers of altered 
feeding patterns, which may exacerbate IHPS risk through 
other causative pathways. The essential role of phosphati-
dylcholines in cholesterol metabolism (Cole et al. 2012) 
warrants further investigation, given our previous findings 
of lower levels of total cholesterol (TC) in umbilical cord 
blood of IHPS cases vs. controls (Feenstra et al. 2013), 
genome-wide genetic correlations of IHPS and cholesterol 
levels (Fadista et al. 2019), and the reported high incidence 
of IHPS in children with SLOS (Kelley and Hennekam 
2000), caused by a cholesterol biosynthesis defect (Tint et al. 
1994). Future studies are required to reveal how genetic and 
environmental factors may contribute to the pathogenesis 
of IHPS through disturbances of the lipid metabolism of 
newborns.
Despite the epidemiological evidence that boys have a 4- 
to 5-fold higher IHPS risk than girls (MacMahon 2006), and 
that sex differences exist in serum lipids and lipoproteins at 
birth (Carlson and Hardell 1977), we did not detect sex dif-
ferences in the concentrations of the IHPS associated metab-
olites. The use of small amounts of sample material from 
dried blood spot samples and the targeted metabolomics 
approach is a limitation of the study, meaning that relevant 
metabolites with potential sex differences could have been 
overlooked. Also, the early sampling time (median of 2 to 6 
days after birth) days to weeks before typical occurrence of 
first IHPS symptoms (2 to 8 weeks after birth) means that 
potential later differences between the sexes in metabolite 
levels could have been overlooked.
The study had additional limitations, including the lack 
of general information on breast-feeding vs. formula feed-
ing so there was no possibility to study the feeding effect 
directly. In addition, genetic variation known to associ-
ate with levels of metabolites queried here is only known 
in adults, and so genetic associations specific to newborn 
metabolite levels might have been missed. Strengths of the 
study include the use of a well-established targeted metabo-
lomics platform (Biocrates) to investigate the association 
between IHPS and 148 metabolites from DBS samples taken 
a few days after birth. To our knowledge, this is the first 
time that extensive newborn metabolomics profiling is being 
used to study IHPS. Another strength of the study is the 
use of well-defined codes from nation-wide Danish registers 
to define outcome, exclusions, and covariates. Finally, the 
study design in which there was a 1-to-1 matching of IHPS 
cases and controls based on sex and exact day of birth is also 
a strength of the study improving efficiency of the analyses.
The observations of this study have implications for 
ongoing studies of complex diseases in which both genetics 
and environmental factors play a role in disease etiology. In 
time, a detailed molecular dissection of IHPS risk factors 
could potentially be used as a basis for more rapid identifica-
tion of particularly susceptible newborns. While this study 
represents a step in that direction, further efforts are needed 
to replicate these findings in other populations and to better 
understand the interplay of genetics and early feeding pat-
terns and consequent progression to IHPS. Specifically, the 
use of wide lipid profiling in nutritional intervention studies 
could help to unravel causal relationships and underlying 
mechanisms and optimize the nutritional composition of 
infant formulas. Moreover, since AC(2:0) is already present 
on the list of most of newborn screening panels worldwide 
(McHugh et al. 2011), future work could address the predic-
tive power of AC(2:0) as a newborn screening test for IHPS, 
and could point to potential preventive and therapeutic tar-
gets to those susceptible to IHPS from birth.
5  Conclusions
Although IHPS is highly heritable (Krogh et  al. 2010; 
Fadista et al. 2019), it is a complex disease that does not 
have Mendelian transmission through families. Common 
genetic variants (Fadista et al. 2019; Feenstra et al. 2013; 
Feenstra et al. 2012) and environmental risk factors (Lund 
et al. 2014; Krogh et al. 2012a; McAteer et al. 2013; Krogh 
et al. 2012b; Zhu et al. 2017) have been previously discov-
ered, but IHPS etiology remains incompletely understood. In 
this case–control metabolomics study of IHPS, we detected 
lower levels of PC(38:4), together with correlated PCs, histi-
dine and AC(2:0), in IHPS. Several lines of evidence suggest 
that environmental factors affecting these metabolites such 
as feeding pattern in the first days of life may underlie the 
associations. Further understanding of the complex interplay 
of genetics and early life environmental factors is critical 
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to the understanding of the pathophysiology, diagnosis and 
possible treatment or prevention of IHPS, and can serve as 
a model for other complex diseases.
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